MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2026.2670890

Медицинская библиотека · The Journal of dermatological treatment · 2026

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

Zhao Yan, Zhang Litao, Wu Liming, Yang Bin, Wang Jinyan, Li Yumei, Diao Qingchun, Li Jingyi, Sun Qing, Zhu Xiaohong, Man Xiaoyong, Wang Lihua, Feng Yanyan, Cai Tao, Zeng Huiming, Li Linfeng, Lu Jianyun, Ren Hong, Li Fuqiu, Lu Qianjin, Tao Xiaohua, Xiao Rong, Ji Chao, Zhao Wenjie, Chu Wei, Chen Bo, Zhang Jianzhong

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

This post-hoc analysis of CM310AD005 conductedaimed to analyze the efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis (AD) with and without prior systemic treatment.

METHODS

In CM310AD005, eligible patients were randomized 1:1 to receive stapokibart 600 (loading dose)-300 mg and placebo Q2W for 16 weeks; all patients subsequently received stapokibart 300 mg Q2W for 36 weeks.

RESULTS

At week 16, in systemic treatment-naïve patients, stapokibart led to significantly higher response rates than placebo for ≥75% improvement from baseline in the Eczema Area and Severity Index score (EASI-75, 70.3% vs. 29.1%), EASI-90 (38.1% vs. 13.3%), Investigator's Global Assessment score of 0 or 1 (45.2% vs. 19.4%), and ≥4-point reduction in weekly average of daily Peak Pruritus Numerical Rating Scale score (34.8% vs. 13.9%) (all p < 0.0001). Among patients with prior systemic treatment, these response rates were also significantly higher in the stapokibart group, reaching 61.5% vs. 19.3%, 35.4% vs. 7.2%, 42.7% vs. 9.6%, and 37.5% vs. 7.2% (all p < 0.0001), respectively. All patients showed further improvements through week 52. The most common treatment-emergent adverse events were infections and infestations, occurring in 61.6% and 70.5% of patients with and without prior systemic treatment.

CONCLUSIONS

Stapokibart demonstrated significant clinical efficacy and manageable safety in AD patients irrespective of prior systemic treatment.

Для цитирования: Zhao Yan, Zhang Litao, Wu Liming, Yang Bin, Wang Jinyan, Li Yumei, Diao Qingchun, Li Jingyi, Sun Qing, Zhu Xiaohong, Man Xiaoyong, Wang Lihua, Feng Yanyan, Cai Tao, Zeng Huiming, Li Linfeng, Lu Jianyun, Ren Hong, Li Fuqiu, Lu Qianjin, Tao Xiaohua, Xiao Rong, Ji Chao, Zhao Wenjie, Chu Wei, Chen Bo, Zhang Jianzhong. Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.. The Journal of dermatological treatment. 2026. DOI: 10.1080/09546634.2026.2670890.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.